Opexa says MS vaccine trial yields positive data
Reuters - USA
O: Quote, Profile, Research) said data from an early-stage
dose escalation trial for Tovaxin, a T-cell vaccine for
multiple sclerosis, was positive and ...
See all stories on this topic

Market Report -- In Play (OPXA)
MSN Money - USA
Opexa Therapeutics reports positive top-line data in
Phase I/II dose escalation trial with Tovaxin for
multiple sclerosis Co announces positive top-line ...
See all stories on this topic

Opexa reports positive MS vaccine data
Pharmaceutical Business Review - USA
Opexa Therapeutics has reported positive data in a
phase I/II dose escalation clinical trial of the investigational
T-cell vaccine, Tovaxin, for multiple ...
See all stories on this topic

Pharma Sector: Few Newsmakers Of The Week - Pfizer, Merck, Glaxo ...
Trading Markets - Los Angeles,CA,USA
However, it remains to be seen if Tovaxin's early
promise eventually translates to a marketable drug, as
it still has a long way to go to reach the shelf of ...
See all stories on this topic

Opexa Reports Positive Data For Phase I/II Dose Escalation Trial ...
Trading Markets - Los Angeles,CA,USA
The Tovaxin Phase IIb clinical study is a multicenter,
randomized, double blind, placebo-controlled trial, enrolling
up to 150 patients. ...
See all stories on this topic